In yesterday’s Wall Street session, Iterum Therapeutics Plc (NASDAQ:ITRM) shares traded at $1.43, down -23.94% from the previous session.
ITRM stock price is now 28.28% away from the 50-day moving average and 4.78% away from the 200-day moving average. The market capitalization of the company currently stands at $32.48M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On March 15, 2021, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $2.50, while ‘RBC Capital Mkts’ rates the stock as ‘Sector Perform’
In other news, Dunne Michael W., Director bought 25,000 shares of the company’s stock on Dec 22 ’23. The stock was bought for $35,000 at an average price of $1.40. Upon completion of the transaction, the Director now directly owns 113,754 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 18 ’23, Director Dunne Michael W. bought 10,000 shares of the business’s stock. A total of $18,442 was incurred on buying the stock at an average price of $1.84. This leaves the insider owning 88,754 shares of the company worth $0.13 million. A total of 3.33% of the company’s stock is owned by insiders.
During the past 12 months, Iterum Therapeutics Plc has had a low of $0.64 and a high of $2.50. The fifty day moving average price for ITRM is $1.11074 and a two-hundred day moving average price translates $1.36051 for the stock.
The latest earnings results from Iterum Therapeutics Plc (NASDAQ: ITRM) was released for 2024-06-30. The company reported revenue of $3.98 million for the quarter, compared to $10.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -63.26 percent.
